trending Market Intelligence /marketintelligence/en/news-insights/trending/jdx5USuxDSHF5BkvhqiXUg2 content esgSubNav
In This List

Neurotrope CEO resigns; replacement named

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Neurotrope CEO resigns; replacement named

Neurotrope Inc. appointed Charles Ryan as CEO and director after the resignation of Susanne Wilke.

Ryan's appointment as director is effective Dec. 18, and he will assume the role of CEO effective Feb. 15, 2018.

Currently, Ryan serves as the CEO and president of Orthobond Corp.

Neurotrope develops treatments for Alzheimer's and other neurodegenerative diseases.